<DOC>
	<DOCNO>NCT00132054</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , amrubicin irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose amrubicin give together irinotecan treat patient recurrent relapse extensive stage small cell lung cancer .</brief_summary>
	<brief_title>Amrubicin Irinotecan Treating Patients With Recurrent Relapsed Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose amrubicin combine irinotecan patient recurrent relapse extensive stage small cell lung cancer . Secondary - Determine response rate patient treat regimen . - Determine overall survival patient treat regimen . - Determine frequency severity adverse event patient treat regimen . OUTLINE : This dose-escalation study amrubicin . Patients receive amrubicin day 1 irinotecan IV day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos amrubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 1/3 ( 33 % ) patient experience dose-limiting toxicity . An additional 6 patient treated MTD . PROJECTED ACCRUAL : A total 6-30 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer Extensive stage disease Recurrent relapse disease 12 prior chemotherapy and/or radiotherapy regimens No unmanageable massive pleural effusion pericardial effusion chest CT scan No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 3 month Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.5 g/dL Hepatic ALT AST ≤ 2 time upper limit normal Bilirubin ≤ 1.5 mg/dL Renal Creatinine normal Cardiovascular No uncontrolled hypertension No unstable angina No congestive heart failure No myocardial infarction within past year No ventricular arrhythmia require medical intervention No serious cardiovascular disease Pulmonary Arterial oxygen pressure ( PaO_2 ) ≥ 70 torr No interstitial pneumonitis pulmonary fibrosis chest xray Gastrointestinal No serious diarrhea No paralytic obstructive ileus Other Not pregnant nursing No uncontrolled diabetes No severe infectious disorder PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior anthracycline derivative &gt; upper dose limit ( e.g. , daunorubicin ≥ 25 mg/kg , doxorubicin ≥ 500 mg/m^2 , epirubicin ≥ 900 mg/m^2 ) Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>